Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 1 day agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 8 hours agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Bill headed to Pritzker's desk will screen babies for Duchenne muscular dystrophy
Chicago Sun-Times· 5 hours agoMy wife and I could’ve never guessed a blood test would send our world crashing into a fatal...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 12 hours agoPfizer’s PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 1 day agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
WATCH: Organization modifies Valley family's home for free to help kids in wheelchairs
ABC 15 Phoenix· 1 hour agoA Valley family is navigating day-to-day life a little easier thanks to a local organization’s...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 1 day agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 2 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical ...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 2 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 2 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...